Identification of Novel CYP2E1 Inhibitor to Investigate Cellular and Exosomal CYP2E1-Mediated Toxicity
Date of Award
Doctor of Philosophy (PhD)
Santosh Kumar, Ph.D.
Chandravanu Dash, Wei Li, Bernd Meibohm, Charles R. Yates
Acetaminophen, Alcohol, CYP2E1, Diallyl Sulfide, Plasma exosomes, Toxicity
Cytochrome P450 2E1 (CYP2E1)-mediated hepatic and extra-hepatic toxicity is of significant clinical importance. Diallyl sulfide (DAS) has been shown to prevent xenobiotics such as alcohol- (ALC/ETH), acetaminophen- (APAP) induced toxicity and disease (e.g. HIV-1) pathogenesis. DAS imparts its beneficial effect by inhibiting CYP2E1-mediated metabolism of xenobiotics, especially at high concentration. However, DAS also causes toxicity at relatively high dosages and with long exposure times. The objective of the first project was to find potent DAS analogs which can replace DAS as a research tool or as potential adjuvant therapy in CYP2E1-mediated pathologies.
Rahman, Mohammad Arifur (0000-0002-5589-0114), "Identification of Novel CYP2E1 Inhibitor to Investigate Cellular and Exosomal CYP2E1-Mediated Toxicity" (2019). Theses and Dissertations (ETD). Paper 482. http://dx.doi.org/10.21007/etd.cghs.2019.0474.